The Bioasis xB3 patented platform provides researchers with a solution to one of medicine’s most stubborn challenges: how to transport medicines across the blood-brain barrier at doses sufficient to have a therapeutic effect.
Scientists at Bioasis have worked for over a decade to develop our proprietary xB3 platform. Formerly called the Transcend-peptide, xB3 is based on a human transport protein found circulating in low levels in the blood. The xB3 platform has shown high efficacy in its ability to shuttle molecules across the blood-brain barrier and reach its targets within the brain through a process called receptor-mediated transcytosis.
Transcytosis occurs when molecules attach to receptors on the cell surface of endothelial cells forming the blood-brain barrier. The receptors pull the molecules by vesicular transport through the cells, gaining access to the brain. Preclinical studies have demonstrated that the xB3 platform can transport molecules of varying sizes and types including monoclonal antibodies, enzymes, small molecules, small-interfering RNA (siRNA) and other types of gene therapies into the brain. xB3 has the potential to treat numerous brain and other central nervous system (CNS) diseases and disorders, including brain cancers and metabolic and neurodegenerative diseases.
The value of the xB3 platform is the potential it has to turn non-brain-penetrating drugs into novel medical entities. The xB3 platform presents the opportunity to deliver medicines into the brain that were previously ineffective in treating the neurological aspects of a disease in a noninvasive manner. Like a key designed to open a lock, the xB3 platform unlocks the door to the blood-brain barrier, allowing entry of therapeutics into the brain. These treatments are not just “biobetters;” they have the potential to be new, differentiated products that bring hope to patients in need.